Recent advances in the management of gastrointestinal stromal tumors

This report focuses mainly on the major reduction of the risk of relapse of gastrointestinal stromal tumor (GIST) treated with imatinib, as identified in the American College of Surgeons Oncology Group (ACOSOG) Z9001 trial. It also focuses on the many unknowns associated with adjuvant imatinib thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Duffaud, Florence, Salas, Sebastien, Huynh, Thanh
Formato: Texto
Lenguaje:English
Publicado: Medicine Reports Ltd 2010
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950054/
https://www.ncbi.nlm.nih.gov/pubmed/20948849
http://dx.doi.org/10.3410/M2-36
Descripción
Sumario:This report focuses mainly on the major reduction of the risk of relapse of gastrointestinal stromal tumor (GIST) treated with imatinib, as identified in the American College of Surgeons Oncology Group (ACOSOG) Z9001 trial. It also focuses on the many unknowns associated with adjuvant imatinib therapy despite approvals by the US Food and Drug Administration and the European Medicines Agency, and on a new marker for the diagnosis of GIST.

Ejemplares similares